161 related articles for article (PubMed ID: 36846652)
1. Sustained response off therapy after fostamatinib: A chronic refractory ITP case report.
Auteri G; Biondo M; Mazzoni C; Venturi M; Romagnoli AD; Paglia S; Cavo M; Vianelli N; Palandri F
Heliyon; 2023 Feb; 9(2):e13462. PubMed ID: 36846652
[TBL] [Abstract][Full Text] [Related]
2. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
McKeage K; Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(10):451-456. PubMed ID: 30459507
[TBL] [Abstract][Full Text] [Related]
3. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
4. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series.
Liu J; Hsia CC
Adv Hematol; 2022; 2022():8119270. PubMed ID: 36393999
[TBL] [Abstract][Full Text] [Related]
6. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ; Izak M; Bussel JB
Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
[TBL] [Abstract][Full Text] [Related]
7. Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.
Lucchesi A; Fattizzo B; De Stefano V; Ruggeri M; Siragusa S; Vianelli N; Zaja F; Rodeghiero F
Ther Adv Hematol; 2023; 14():20406207221147777. PubMed ID: 37426835
[TBL] [Abstract][Full Text] [Related]
8. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez TJ; Bermejo N; Cardesa-Cabrera R; Martínez V; Aguilar-Monserrate G; Pérez Segura G; García AD; Luis-Navarro J; Lakhwani S; Acedo N; Lozano ML; Bernat S; Torres-Tienza A; Ruano A; Jarque I; Galán Alvarez P; Benet Campos C; Marcellini-Antonio S; Jimenez-Bárcenas R; Martínez-Carballeira D; de Miguel Llorente D; Perona Blázquez Á; González-Gascón-Y-Marín I; Lopez-Ansoar E; Alonso Alonso JM; Bengochea-Casado ML; Díaz Gálvez FJ; Moretó A; Moreno G; Hernández-Martin R; de Cabo E; Davila-Valls J; Cuesta A; Pastoriza Cruz C; Hermida G; García C; Pozas-Mañas MA; Aguilar-Franco C; Fernandez-Jimenez D; Navas-Elorza B; López-Santamaría Castro C; Lorenzo Vizcaya A; Ortín X; Pintos MG; Piernas S; Díaz-Santa J; Soto-Ortega I; Provan D; García-Donas Gabaldón G
Blood; 2024 Jun; ():. PubMed ID: 38843478
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials.
Tungjitviboonkun S; Bumrungratanayos N; Jitwimungsanon J; Kheamakulvanich T; Siramongkholkarn S
Ann Hematol; 2024 Jun; ():. PubMed ID: 38856778
[TBL] [Abstract][Full Text] [Related]
10. Immune thrombocytopenia.
Bussel J; Cooper N; Boccia R; Zaja F; Newland A
Expert Rev Hematol; 2021 Nov; 14(11):1013-1025. PubMed ID: 34720027
[TBL] [Abstract][Full Text] [Related]
11. Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib.
Innao V; Calogero RD; Lo Presti F; Consoli U
Case Rep Hematol; 2023; 2023():9953245. PubMed ID: 37323813
[TBL] [Abstract][Full Text] [Related]
12. Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series.
Hughes DM; Toste C; Nelson C; Escalon J; Blevins F; Shah B
J Adv Pract Oncol; 2021 Jul; 12(5):508-517. PubMed ID: 34430061
[TBL] [Abstract][Full Text] [Related]
13. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.
Cooper N; Altomare I; Thomas MR; Nicolson PLR; Watson SP; Markovtsov V; Todd LK; Masuda E; Bussel JB
Ther Adv Hematol; 2021; 12():20406207211010875. PubMed ID: 33995988
[TBL] [Abstract][Full Text] [Related]
14. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Ghadaki B; Nazi I; Kelton JG; Arnold DM
Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of immune thrombocytopenia.
Červinek L
Vnitr Lek; 2018; 64(5):526-529. PubMed ID: 30193522
[TBL] [Abstract][Full Text] [Related]
17. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
Mahévas M; Gerfaud-Valentin M; Moulis G; Terriou L; Audia S; Guenin S; Le Guenno G; Salles G; Lambotte O; Limal N; Viallard JF; Cheze S; Tomowiak C; Royer B; Neel A; Debouverie O; Hot A; Durieu I; Perlat A; Cliquennois M; Deteix C; Michel M; Godeau B
Blood; 2016 Sep; 128(12):1625-30. PubMed ID: 27354722
[TBL] [Abstract][Full Text] [Related]
20. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A; Lee EJ; McDonald V; Bussel JB
Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]